摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(furo[3,2-c]pyridin-2-yl)ethan-1-amine | 1518581-43-5

中文名称
——
中文别名
——
英文名称
1-(furo[3,2-c]pyridin-2-yl)ethan-1-amine
英文别名
1-{Furo[3,2-c]pyridin-2-yl}ethan-1-amine;1-furo[3,2-c]pyridin-2-ylethanamine
1-(furo[3,2-c]pyridin-2-yl)ethan-1-amine化学式
CAS
1518581-43-5
化学式
C9H10N2O
mdl
——
分子量
162.191
InChiKey
GRRYGMAFEKWZSG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    52
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    (S)-N-(1-(furo[3,2-c]pyridin-2-yl)ethyl)-2-methylpropane-2-sulfinamide 在 盐酸 作用下, 以 甲醇 为溶剂, 反应 1.0h, 以38%的产率得到1-(furo[3,2-c]pyridin-2-yl)ethan-1-amine
    参考文献:
    名称:
    EP3404021
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR
    申请人:Nippon Chemiphar Co., Ltd.
    公开号:EP3404021A1
    公开(公告)日:2018-11-21
    A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2, provide that n and m are not 0 and 2 at the same time.
    由以下通式(I)代表的化合物、该化合物的同系物或立体异构体、其药学上可接受的盐或其溶液可用作电压依赖性 T 型钙通道阻滞剂: 其中 A 代表可具有取代基的融合环,该融合环由 5 元杂芳基或 5 元或 6 元杂环和苯环或类似物组成,5 元杂芳基具有 1 至 3 个相同或不同的杂原子作为成环元素,具有至少一个取代基,例如具有 1 至 8 个碳原子并被 1 至 5 个卤素原子取代的烷氧基;R 代表氢原子或类似物;B 代表 CR5(Q1) 或 NQ2,其中 Q1 代表可能具有取代基的苯并咪唑基;Q2 代表可能具有取代基的具有 1 至 8 个碳原子的烷基、可能具有取代基的杂芳基或类似物;R0、R1、R2、R3、R4 和 R5 各代表氢原子或类似物;n 和 m 各代表 0、1 或 2,但 n 和 m 不能同时为 0 和 2。
  • VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER
    申请人:Nippon Chemiphar Co., Ltd.
    公开号:US20190077767A1
    公开(公告)日:2019-03-14
    A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2, provide that n and m are not 0 and 2 at the same time.
查看更多

同类化合物

环丁[b]呋喃并[3,2-d]吡啶 环丁[b]呋喃并[2,3-d]吡啶 拟芸香定 呋喃并[3,2-c]吡啶-7-甲腈 呋喃并[3,2-c]吡啶-7-基甲醇 呋喃并[3,2-c]吡啶-6-甲醛 呋喃并[3,2-c]吡啶-6-基甲醇 呋喃并[3,2-c]吡啶-4-甲醛 呋喃并[3,2-c]吡啶-4-甲腈 呋喃并[3,2-c]吡啶-4-基甲醇 呋喃并[3,2-c]吡啶-3-甲腈 呋喃并[3,2-c]吡啶-2-羧醛 呋喃并[3,2-c]吡啶-2-羧酸 呋喃并[3,2-c]吡啶-2-磺酰胺 呋喃并[3,2-c]吡啶-2-甲腈 呋喃并[3,2-c]吡啶-2-甲胺 呋喃并[3,2-b]吡啶4-氧化物 呋喃并[3,2-b]吡啶-7-甲腈 呋喃并[3,2-b]吡啶-6-酚 呋喃并[3,2-b]吡啶-6-基甲醇 呋喃并[3,2-b]吡啶-5-羧醛 呋喃并[3,2-b]吡啶-5-甲腈 呋喃并[3,2-b]吡啶-3-甲腈 呋喃并[3,2-b]吡啶-2-羧醛 呋喃并[3,2-b]吡啶-2-羧酸 呋喃并[3,2-b]吡啶-2-磺酰胺 呋喃并[3,2-b]吡啶-2-甲醇 呋喃并[3,2-b]吡啶-2-甲腈 呋喃并[3,2-b]吡啶 呋喃并[3,2-C]吡啶-7-基甲醇 呋喃并[2,3-c]吡啶6-氧化物 呋喃并[2,3-c]吡啶-7-甲醛 呋喃并[2,3-c]吡啶-7-甲腈 呋喃并[2,3-c]吡啶-7(6h)-酮 呋喃并[2,3-c]吡啶-5-甲醇 呋喃并[2,3-c]吡啶-3-甲腈 呋喃并[2,3-c]吡啶-2-羰酰氯 呋喃并[2,3-c]吡啶-2-羧酸 呋喃并[2,3-c]吡啶-2-磺酰胺 呋喃并[2,3-c]吡啶-2-甲腈 呋喃并[2,3-c]吡啶-2-基甲醇 呋喃并[2,3-c]吡啶,3-乙氧基- 呋喃并[2,3-b]吡啶7-氧化物 呋喃并[2,3-b]吡啶-6-甲醛 呋喃并[2,3-b]吡啶-6-甲腈 呋喃并[2,3-b]吡啶-6(7H)-酮 呋喃并[2,3-b]吡啶-5-醇 呋喃并[2,3-b]吡啶-5-胺 呋喃并[2,3-b]吡啶-5-甲腈 呋喃并[2,3-b]吡啶-5-基甲醇